产品
编 号：F432760
分子式：C19H19ClN3NaO6S
分子量：475.88
分子式：C19H19ClN3NaO6S
分子量：475.88
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
240
In-stock
500mg
400
In-stock
结构图
CAS No: 7081-44-9
产品详情
生物活性：
Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins.
体内研究：
Cloxacillin sodium monohydrate (1.6125 mg/kg; s.c.; 12-h intervals for 72 h) protects mice from S. aureus peritonitis in vivo when combines with Thioridazine and Tetracycline.Cloxacillin sodium monohydrate (7.5 mg/per; i.p.; twice daily from day 3 for 3 days) develops less severe synovitis and reduces bone erosions when combines with anti-IL-15 antibodies.Animal Model:Female BALB/c mice (6-week-old; peritonitis model).
Dosage:1.6125 mg/kg (combines with TC (3.125 mg/kg) and TZ (25 mg/kg))
Administration:Subcutaneous injection; 12-h intervals for 72 h.
Result:Reduced the degree of inflammatory cell infiltration in the mouse lung tissue and alveolar structures tended to be normal.Significantly reduced the pathological changes in spleen and liver tissue, as well as decreased the CFU counts of S. aureus in the peritoneal cavity.
Animal Model:Female wildtype C57BL/6 mice (8-week-old; systemic S. aureus-induced arthritis model)
Dosage:7.5 mg/per (combines with 25 μg/per anti-IL-15 antibodies)
Administration:Intraperitoneal injection; twice daily from day 3 (after bacterial inoculation) and stopped at day 6.
Result:Showed activities of reducing severe synovitis and bone erosions when combined with anti-IL-15 antibodies.
体外研究：
Cloxacillin sodium monohydrate (0-2048 μg/mL; 20-24 h) shows good antibacterial activity for S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL.Cloxacillin sodium monohydrate (0.015625 μg/mL; 6 h) inhibits the hemolytic activity of Hlα in vitro, and this inhibition is not only more pronounced when combined with TZ and TZ, but also suppresses the inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins.
Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins.
体内研究：
Cloxacillin sodium monohydrate (1.6125 mg/kg; s.c.; 12-h intervals for 72 h) protects mice from S. aureus peritonitis in vivo when combines with Thioridazine and Tetracycline.Cloxacillin sodium monohydrate (7.5 mg/per; i.p.; twice daily from day 3 for 3 days) develops less severe synovitis and reduces bone erosions when combines with anti-IL-15 antibodies.Animal Model:Female BALB/c mice (6-week-old; peritonitis model).
Dosage:1.6125 mg/kg (combines with TC (3.125 mg/kg) and TZ (25 mg/kg))
Administration:Subcutaneous injection; 12-h intervals for 72 h.
Result:Reduced the degree of inflammatory cell infiltration in the mouse lung tissue and alveolar structures tended to be normal.Significantly reduced the pathological changes in spleen and liver tissue, as well as decreased the CFU counts of S. aureus in the peritoneal cavity.
Animal Model:Female wildtype C57BL/6 mice (8-week-old; systemic S. aureus-induced arthritis model)
Dosage:7.5 mg/per (combines with 25 μg/per anti-IL-15 antibodies)
Administration:Intraperitoneal injection; twice daily from day 3 (after bacterial inoculation) and stopped at day 6.
Result:Showed activities of reducing severe synovitis and bone erosions when combined with anti-IL-15 antibodies.
体外研究：
Cloxacillin sodium monohydrate (0-2048 μg/mL; 20-24 h) shows good antibacterial activity for S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL.Cloxacillin sodium monohydrate (0.015625 μg/mL; 6 h) inhibits the hemolytic activity of Hlα in vitro, and this inhibition is not only more pronounced when combined with TZ and TZ, but also suppresses the inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备